Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neurox
- Development stage
- Unknown
- Lead developer
- Escape Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Neurox is a muscle-paralyzing agent being developed by Escape Therapeutics for both therapeutic and cosmetic applications. It is designed to reduce muscle activity, targeting indications such as spasticity and the reduction of facial wrinkles. The drug is characterized as either a small molecule or a biologic, though its specific molecular target and mechanism of action have not been publicly disclosed. According to company pipeline information, Neurox is in preclinical development for spasticity and has progressed to clinical stages for wrinkle reduction, with Phase 1 being the most likely current status.
- Brand names
- Neurox
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on Neurox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurox.